Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

作者：Bradon R. McDonald, Tania Contente‐Cuomo, Stephen‐John Sammut, Ahuva Odenheimer-Bergman, Brenda Ernst, Nieves Perdigones, Suet‐Feung Chin, Maria Farooq, Rosa Mejia, Patricia A. Cronin, Karen S. Anderson, Heidi Kosiorek, Donald W. Northfelt, Ann E. McCullough, Bhavika Patel, Jeffrey N. Weitzel, Thomas P. Slavin, Carlos Caldas, Barbara A. Pockaj, Muhammed Murtaza · 发表于：Science Translational Medicine · 年份：2019 · DOI：10.1126/scitranslmed.aax7392 · 被引用次数：312 · 研究领域：Cancer Genomics and Diagnostics、Cancer Cells and Metastasis、Genetic factors in colorectal cancer

= 0.0057, AUC = 0.83). In addition, patients with pathCR showed a larger decrease in ctDNA concentrations during neoadjuvant therapy. These results demonstrate high accuracy for assessment of molecular response and residual disease during neoadjuvant therapy using ctDNA analysis. TARDIS has achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, demonstrating that personalized ctDNA tracking could enable individualized clinical management of patients with cancer treated with curative intent.